Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Position Raised by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 64.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 10,942 shares of the biopharmaceutical company’s stock after purchasing an additional 4,272 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Agios Pharmaceuticals were worth $486,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter worth $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals in the 2nd quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares during the period. CWM LLC grew its stake in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $216,000.

Wall Street Analyst Weigh In

Several research firms recently commented on AGIO. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Finally, StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 16th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $52.00.

Agios Pharmaceuticals Trading Down 1.1 %

AGIO stock opened at $46.30 on Thursday. The firm has a market cap of $2.63 billion, a PE ratio of -7.33 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a 1 year low of $20.35 and a 1 year high of $53.28. The company has a fifty day simple moving average of $44.68 and a 200 day simple moving average of $42.01.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. Agios Pharmaceuticals’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.51) EPS. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -4.87 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.